ストックスクリーナーアプリを入手
20.99
0.59%
-0.1882
前日終値:
$21.18
開ける：
$21.46
24時間の取引高:
240.89K
Relative Volume:
0.76
時価総額：
$717.44M
収益：
-
当期純損益:
$-81.05M
株価収益率:
-8.0024
EPS:
-2.6232
ネットキャッシュフロー:
$-68.97M
1週間 パフォーマンス:
-2.30%
1か月 パフォーマンス:
-8.10%
6か月 パフォーマンス:
-26.89%
1年 パフォーマンス:
-5.92%
1日の値動き範囲:
$20.77
$21.50
1週間の範囲:
$20.77
$22.29
52週間の値動き範囲:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
AVBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.97 | 777.21M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.85 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.22 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.80 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.31 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.37 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
Is ArriVent BioPharma Inc. a growth stock or a value stockAchieve consistent double-digit returns - jammulinksnews.com
News impact scoring models applied to ArriVent BioPharma Inc.AI-Based Reversal Point Prediction Signal - Newser
Using data models to predict ArriVent BioPharma Inc. stock movementFree Weekly Hot Picks With Buy Confidence - Newser
ArriVent BioPharma Inc. stock trend forecast Free Reversal Alert Based on RSI Indicator - Newser
Using data models to predict ArriVent BioPharma Inc. stock movement Low Risk Trade Timing with Analysis Metrics - Newser
ArriVent BioPharma Inc. recovery potential after sell off Price Action Based Buy Zone Forecast - Newser
What institutional investors are buying ArriVent BioPharma Inc. stockFree Daily Trading Room Entry - jammulinksnews.com
What is ArriVent BioPharma Inc. company’s growth strategyBuild a winning investment strategy - jammulinksnews.com
How strong is ArriVent BioPharma Inc. company’s balance sheetUnlock real-time stock alerts for quick profits - jammulinksnews.com
Is ArriVent BioPharma Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
How many analysts rate ArriVent BioPharma Inc. as a “Buy”Exceptional trading performance - jammulinksnews.com
What makes ArriVent BioPharma Inc. stock price move sharplyOptimized Return Investment Picks - Newser
ArriVent BioPharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SaySteady Profit Stock Forecasts - Newser
ArriVent BioPharma Inc. Earnings Report Breakdown: What Investors Should KnowFree Stock Portfolio Optimization - Newser
Is ArriVent BioPharma Inc. stock a growth or value playLow Risk Trade Timing Signals - Newser
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MSN
ArriVent BioPharma Inc. Stock Analysis and ForecastExceptional market positioning - PrintWeekIndia
What risks could impact ArriVent BioPharma Inc. stock performanceLightning-fast capital gains - jammulinksnews.com
Lifesci Capital Issues Positive Estimate for AVBP Earnings - Defense World
Can ArriVent BioPharma Inc. stock recover from recent declineUnprecedented market success - jammulinksnews.com
What analysts say about ArriVent BioPharma Inc. stockExplosive returns - PrintWeekIndia
Is ArriVent BioPharma Inc. a good long term investmentPowerful market insights - Autocar Professional
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of “Buy” from Analysts - Defense World
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial - The Globe and Mail
ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com
ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com Canada
ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks
ArriVent expects topline data from lung cancer drug trial in early 2026 - Investing.com Canada
ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times
New Strong Sell Stocks For July 21st - Barchart.com
New Strong Sell Stocks for July 21st - The Globe and Mail
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
Arrivent Biopharma Inc (AVBP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Sep 19 '24 |
Option Exercise |
3.28 |
27,566 |
90,481 |
124,583 |
0.94%
1.30%
大文字化:
|
ボリューム (24 時間):